The Epidemiology of Prostate Cancer

  • Graham Giles
Part of the Cancer Genetics book series (CANGENETICS)


Prostate cancer presents several enduring challenges that continue to defy solution despite extensive research. It has long been known that prostate tumours become increasingly prevalent with age, so much so that their occurrence could be viewed as part of the normal ageing process, as the vast majority of men will develop them if they live long enough (Giles 2003). Importantly, the preponderance of prostate tumours is of low metastatic potential and of slow growth so, although the majority of older men zealously investigated will be found to have microscopically detectable tumours, most men will die with a prostate tumour rather than from one (Bostwick et al. 2004).

In a minority of cases prostate tumours become invasive and potentially lethal. The conundrum here, elegantly articulated by Boccon-Gibod (1996), is how to distinguish “tigers” from “pussycats”; i.e. how to identify at a curable stage the minority of lethal cancers from the majority of non-aggressive tumours. Answers to this question remain elusive. Schnell and Witte (this volume) focus on inherited aspects of susceptibility to aggressive prostate cancer.


Prostate Cancer Prostate Cancer Risk Advanced Prostate Cancer Beta Carotene Incident Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adami HO, Kuper H, Andersson SO et al (2003) Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 12(9):872–875PubMedGoogle Scholar
  2. Albanes D, Winick M (1988) Are cell number and cell proliferation risk factors for cancer? J Natl Cancer Inst 80:772–774PubMedGoogle Scholar
  3. Albanes D, Heinonen OP, Taylor PR et al (1996) Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88(21):1560–1570PubMedGoogle Scholar
  4. Albertsen PC (1996) Screening for prostate cancer is neither appropriate nor cost-effective. Urol Clin North Am 23(4):521–530PubMedGoogle Scholar
  5. Albertsen PC (2005) Is screening for prostate cancer with prostate specific antigen an appropriate public health measure? Acta Oncol 44(3):255–264PubMedGoogle Scholar
  6. Albertsen PC, Hanley JA, Barrows GH et al (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97(17):1248–1253PubMedGoogle Scholar
  7. Ali AS, Hamdy FC (2007) The spectrum of prostate cancer care: from curative intent to palliation. Curr Urol Rep 8(3):245–252PubMedGoogle Scholar
  8. Allen NE, Key TJ, Appleby PN et al (2007) Serum insulin-like growth factor (IGF) -I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 16(6):1121–1127PubMedGoogle Scholar
  9. Anttila T, Tenkanen L, Lumme S et al (2005) Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 14(2):385–389PubMedGoogle Scholar
  10. Augustsson K, Michaud DS, Rimm EB et al (2003) A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 12(1):64–67PubMedGoogle Scholar
  11. Aumuller G (1991) Postnatal development of the prostate. Bull Assoc Anat (Nancy) 75:39–42Google Scholar
  12. Baron JA, Beach M, Wallace K et al (2005) Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 14(3):586–589PubMedGoogle Scholar
  13. Beemsterboer PM, de Koning HJ, Kranse R et al (2000) Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. J Urol 164(4):1216–1220PubMedGoogle Scholar
  14. Bill-Axelson A, Holmberg L, Filén F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100(16):1144–1154PubMedGoogle Scholar
  15. Blutt SE, Weigel NL (1999) Vitamin D and prostate cancer. Proc Soc Exp Biol Med 221:89–98PubMedGoogle Scholar
  16. Boccon-Gibod L (1996) Significant versus insignificant prostate cancer – can we identify the tigers from the pussy cats? J Urol 156(3):1069–1070PubMedGoogle Scholar
  17. Boland LL, Mink PJ, Bushhouse SA et al (2003) Weight and length at birth and risk of early-onset prostate cancer (United States). Cancer Causes Control 14(4):335–338PubMedGoogle Scholar
  18. Bosland MC (2005) The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev Urol 7(Suppl 3):S4–S10PubMedGoogle Scholar
  19. Bosland MC (2006) Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann N Y Acad Sci 1089:168–176PubMedGoogle Scholar
  20. Bostwick DG, Chang L (1999) Overdiagnosis of prostatic adenocarcinoma. Semin Urol Oncol 17(4):199–205PubMedGoogle Scholar
  21. Bostwick DG, Burke HB, Djakiew D et al (2004) Human prostate cancer risk factors. Cancer 101(10 Suppl):2371–2490PubMedGoogle Scholar
  22. Boyle P, Severi G, Giles GG (2003) The epidemiology of prostate cancer. Urol Clin North Am 30(2):209–217PubMedGoogle Scholar
  23. Brawley OW (1997) Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 80(9):1857–1863PubMedGoogle Scholar
  24. Breslow RA, Weed DL (1998) Review of epidemiologic studies of alcohol and prostate cancer: 1971–1996. Nutr Cancer 30:1–13PubMedGoogle Scholar
  25. Brinkman M, Reulen RC, Kellen E et al (2006) Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 42(15):2463–2471PubMedGoogle Scholar
  26. Brouwer IA, Katan MB, Zock PL (2004) Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. J Nutr 134(4):919–922PubMedGoogle Scholar
  27. Carruba G (2007) Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 102(4):899–911PubMedGoogle Scholar
  28. Casey G, Neville PJ, Liu X et al (2006) Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 15(5):735–741PubMedGoogle Scholar
  29. Catalona WJ, Loeb S, Han M (2006) Viewpoint: expanding prostate cancer screening. Ann Intern Med 144(6):441–443PubMedGoogle Scholar
  30. Chamie K, Devere White RW et al (2008) Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer 113(9):2464–2470PubMedGoogle Scholar
  31. Chan JM, Stampfer MJ, Ma J et al (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94(14):1099–1106PubMedGoogle Scholar
  32. Chang S, Hursting SD, Contois JH et al (2001) Leptin and prostate cancer. Prostate 46(1):62–67PubMedGoogle Scholar
  33. Chen YC, Giovannucci E, Kraft P et al (2007) Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomarkers Prev 16(10):1982–1989PubMedGoogle Scholar
  34. Cheng I, Liu X, Plummer SJ et al (2007) COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97(4):557–561PubMedGoogle Scholar
  35. Christensen GB, Camp NJ, Farnham JM et al (2007) Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees. Prostate 67(6):605–613PubMedGoogle Scholar
  36. Cicek MS, Conti DV, Curran A et al (2004) Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59(1):69–76PubMedGoogle Scholar
  37. Cicek MS, Liu X, Casey G et al (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 14(9):2173–2177PubMedGoogle Scholar
  38. Cicek MS, Liu X, Schumacher FR et al (2006) Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 15(12):2549–2552PubMedGoogle Scholar
  39. Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276(24):1957–1963PubMedGoogle Scholar
  40. Clarke G, Whittemore AS (2000) Prostate cancer risk in relation to anthropometry and physical activity: the National Health and Nutrition Examination Survey Epidemiological Follow-Up Study. Cancer Epidemiol Biomarkers Prev 9:875–881PubMedGoogle Scholar
  41. Clinton SK, Emenhiser C, Schwartz SJ et al (1996) Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate cancer. Cancer Epidemiol Biomarkers Prev 5:823–833PubMedGoogle Scholar
  42. Conlon EM, Goode EL, Gibbs M et al (2003) Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer 105(5):630–635PubMedGoogle Scholar
  43. Cook NR, Stampfer MJ, Ma J et al (1999) Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 86:1783–1792PubMedGoogle Scholar
  44. Corder EH, Friedman GD, Vogelman JH et al (1995) Seasonal variation in Vitamin D, Vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 4:655–659PubMedGoogle Scholar
  45. Costello LC, Franklin RB (2006) The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 5:17PubMedGoogle Scholar
  46. Cross AJ, Peters U, Kirsh VA et al (2005) A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 65(24):11779–11784PubMedGoogle Scholar
  47. Cui J, Staples MP, Hopper JL et al (2001) Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 68(5):1207–1218PubMedGoogle Scholar
  48. Dagnelie PC, Schuurman AG, Goldbohm RA (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93:1139–1150PubMedGoogle Scholar
  49. Danforth KN, Hayes RB, Rodriguez C et al (2008) Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 29(3):568–572PubMedGoogle Scholar
  50. Dasgupta K, Di Cesar D, Ghosn J et al (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12(2):130–135PubMedGoogle Scholar
  51. De Marzo AM, Platz EA, Sutcliffe S et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256–269PubMedGoogle Scholar
  52. Denis LJ (1995) Prostate cancer screening and prevention: “realities and hope”. Urology 46(3 Suppl A):56–61PubMedGoogle Scholar
  53. Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13(1):72–79PubMedGoogle Scholar
  54. Dennis LK, Dawson DV, Resnick MI (2002) Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy. Prostate Cancer Prostatic Dis 5(3):193–203PubMedGoogle Scholar
  55. Dennis LK, Snetselaar LG, Smith BJ et al (2004) Problems with the assessment of dietary fat in prostate cancer studies. Am J Epidemiol 160(5):436–444PubMedGoogle Scholar
  56. Dillner J, Knekt P, Boman J et al (1998) Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 75:564–567PubMedGoogle Scholar
  57. Dunger DB, Ahmed ML, Ong KK (2006) Early and late weight gain and the timing of puberty. Mol Cell Endocrinol 254–255:140–145PubMedGoogle Scholar
  58. Easton DF, Schaid DJ, Whittemore AS (2003) Where are the prostate cancer genes? A summary of eight genome wide searches. Prostate 57(4):261–269PubMedGoogle Scholar
  59. Eaton NE, Reeves GK, Appleby PN et al (1999) Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80(7):930–934PubMedGoogle Scholar
  60. Edwards SM, Kote-Jarai Z, Meitz J et al (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72(1):1–12PubMedGoogle Scholar
  61. Ekbom A (1998) Growing evidence that several human cancers may originate in utero. Semin Cancer Biol 8(4):237–244PubMedGoogle Scholar
  62. Ekbom A, Hsieh CC, Lipworth L et al (1996) Perinatal characteristics in relation to incidence of and mortality from prostate cancer. BMJ 313(7053):337–341PubMedGoogle Scholar
  63. Ekbom A, Wuu J, Adami HO et al (2000) Duration of gestation and prostate cancer risk in offspring. Cancer Epidemiol Biomarkers Prev 9(2):221–223PubMedGoogle Scholar
  64. Eriksson M, Wedel H, Wallander MA et al (2007) The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age. Prostate 67(11):1247–1254PubMedGoogle Scholar
  65. Etzioni R, Penson DF, Legler JM et al (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13):981–990PubMedGoogle Scholar
  66. Feuer EJ, Merrill RM, Hankey BF (1999) Cancer surveillance series: interpreting trends in prostate cancer – part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91(12):1025–1032PubMedGoogle Scholar
  67. Fincham SM, Hill GB, Hanson J et al (1990) Epidemiology of prostatic cancer: a case-control study. Prostate 17(3):189–206PubMedGoogle Scholar
  68. Franklin RB, Costello LC (2007) Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 463(2):211–217PubMedGoogle Scholar
  69. Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97PubMedGoogle Scholar
  70. Freedland SJ, Giovannucci E, Platz EA (2006) Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 17(1):5–9PubMedGoogle Scholar
  71. Friedenreich CM, Thune I (2001) A review of physical activity and prostate cancer risk. Cancer Causes Control 12(5):461–475PubMedGoogle Scholar
  72. Gade-Andavolu R, Cone LA, Shu S et al (2006) Molecular interactions of leptin and prostate cancer. Cancer J 12(3):201–206PubMedGoogle Scholar
  73. Gallus S, Foschi R, Negri E et al (2007) Dietary zinc and prostate cancer risk: a case-control study from Italy. Eur Urol 52(4):1052–1056PubMedGoogle Scholar
  74. Gann PH, Hennekens CH, Ma J et al (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16):1118–1126PubMedGoogle Scholar
  75. Gann PH, Ma J, Giovannucci E et al (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59(6):1225–1230PubMedGoogle Scholar
  76. Gao X, LaValley MP, Tucker KL (2005) Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 97(23):1768–1777PubMedGoogle Scholar
  77. Gennigens C, Menetrier-Caux C, Droz JP (2006) Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 58(2):124–145PubMedGoogle Scholar
  78. Giles GG (2003) Epidemiological investigation of prostate cancer. Methods Mol Med 81:1–19PubMedGoogle Scholar
  79. Giles GG, Ireland P (1997) Diet, nutrition and prostate cancer. Int J Cancer 10:13–17PubMedGoogle Scholar
  80. Giles GG, Severi G, English DR et al (2003) Sexual factors and prostate cancer. BJU Int 92(3):211–216PubMedGoogle Scholar
  81. Giovannucci E (2003) Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 35(11–12):694–704PubMedGoogle Scholar
  82. Giovannucci E (2007) Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostate cancer risk. Nutr Rev 65(8 Pt 2):S77–S79PubMedGoogle Scholar
  83. Giovannucci E, Rimm EB, Wolk A et al (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58:442–447PubMedGoogle Scholar
  84. Giovannucci E, Rimm EB, Liu Y et al (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94(5):391–398PubMedGoogle Scholar
  85. Giovannucci E, Rimm EB, Liu Y et al (2003) A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 12(12):1403–1409PubMedGoogle Scholar
  86. Giovannucci E, Rimm EB, Liu Y et al (2004) Height, predictors of C-peptide and cancer risk in men. Int J Epidemiol 33(1):217–225PubMedGoogle Scholar
  87. Giovannucci EL, Liu Y, Leitzmann MF et al (2005) A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 165(9):1005–1010PubMedGoogle Scholar
  88. Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98(7):451–459PubMedGoogle Scholar
  89. Giovannucci E, Liu Y, Platz EA et al (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121(7):1571–1578PubMedGoogle Scholar
  90. Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23(3):273–279PubMedGoogle Scholar
  91. Gohagan JK, Prorok PC, Kramer BS et al (1994) Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 152(5 Pt 2):1905–1909PubMedGoogle Scholar
  92. Gomez JM (2006) The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biotechnol 7(2):125–132PubMedGoogle Scholar
  93. Griffiths K, Denis L, Turkes A et al (1998) Possible relationship between dietary factors and pathogenesis of prostate cancer. Int J Urol 5:195–213PubMedGoogle Scholar
  94. Gyorkey F, Min KW, Huff JA et al (1967) Zinc and magnesium in human prostate gland: normal, hyperplastic, and neoplastic. Cancer Res 27(8):1348–1353PubMedGoogle Scholar
  95. Hafez B, Hafez ES (2004) Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology. Arch Androl 50(2):45–68PubMedGoogle Scholar
  96. Harris RE, Beebe-Donk J, Doss H et al (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 13(4):559–583PubMedGoogle Scholar
  97. Hedelin M, Chang ET, Wiklund F et al (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120(2):398–405PubMedGoogle Scholar
  98. Heinonen OP, Albanes D, Virtamo J et al (1998) Prostate cancer and supplementation with alpha-tocopherol and betacarotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446PubMedGoogle Scholar
  99. Helzlsouer KJ, Erlinger TP, Platz EA (2006) C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 42(6):704–707PubMedGoogle Scholar
  100. Hemminki K, Rawal R, Bermejo JL (2005) Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 113(2):312–315PubMedGoogle Scholar
  101. Henderson BE, Bernstein L, Ross RK et al (1988) The early in utero estrogen and testosterone environment of blacks and whites – potential effects on male offspring. Br J Cancer 57:216–218PubMedGoogle Scholar
  102. Hercberg S, Galan P, Preziosi P et al (2004) The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 164(21):2335–2342PubMedGoogle Scholar
  103. Heysek RV (2007) Modern brachytherapy for treatment of prostate cancer. Cancer Control 14(3):238–243PubMedGoogle Scholar
  104. Hoffman RM, Clanon DL, Littenberg B et al (2000) Using the Free-to-total Prostate-specific Antigen Ratio to Detect Prostate Cancer in Men with non-specific Elevations of Prostate-specific Antigen Levels. J Gen Intern Med 15(10):739–748PubMedGoogle Scholar
  105. Holick CN, Stanford JL, Kwon EM (2007) Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 16(10):1990–1999PubMedGoogle Scholar
  106. Holt RI (2002) Fetal programming of the growth hormone-insulin-like growth factor axis. Trends Endocrinol Metab 13(9):392–397PubMedGoogle Scholar
  107. Hsi LC, Wilson LC, Eling TE (2002) Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 277(43):40549–40556PubMedGoogle Scholar
  108. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11:1388–1413PubMedGoogle Scholar
  109. Hsing AW, Chua S Jr, Gao YT et al (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93(10):783–789PubMedGoogle Scholar
  110. Hunt CD, Johnson PE, Herbel J et al (1992) Effects of dietary zinc depletion on seminal volume and zinc loss, serum testosterone concentrations, and sperm morphology in young men. Am J Clin Nutr 56(1):148–157PubMedGoogle Scholar
  111. Il’yasova D, Colbert LH, Harris TB et al (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14(10):2413–2418PubMedGoogle Scholar
  112. Isaacs JT (1983) Prostatic structure and function in relation to the etiology of prostate cancer. Prostate 4:351–366PubMedGoogle Scholar
  113. Jacobs EJ, Thun MJ, Bain EB et al (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8):608–615PubMedGoogle Scholar
  114. John EM, Koo J, Schwartz GG (2007) Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol Biomarkers Prev 16(6):1283–1286PubMedGoogle Scholar
  115. Joseph MA, Moysich KB, Freudenheim JL et al (2004) Cruciferous vegetables, genetic polymorphisms in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr Cancer 50(2):206–213PubMedGoogle Scholar
  116. Juul A, Bang P, Hertel NT et al (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744–752PubMedGoogle Scholar
  117. Kambhampati S, Ray G, Sengupta K et al (2005) Growth factors involved in prostate carcinogenesis. Front Biosci 10:1355–1367PubMedGoogle Scholar
  118. Kang D, Lee KM, Park SK et al (2007) Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 16(8):1581–1586PubMedGoogle Scholar
  119. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062PubMedGoogle Scholar
  120. Kerr WK, Keresteci G, Ayohb HM (1960) The distribution of zinc within the human prostate. Cancer 13:550–554PubMedGoogle Scholar
  121. Key TJ, Silcocks PB, Davey GK et al (1997) A case-control study of diet and prostate cancer. Br J Cancer 76:678–687PubMedGoogle Scholar
  122. Key TJ, Allen N, Appleby P et al (2004) Fruits and vegetables and prostate cancer: no association among 1104 cases in a prospective study of 130544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109(1):119–124PubMedGoogle Scholar
  123. Key TJ, Appleby PN, Allen NE et al (2007) Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 86(3):672–681PubMedGoogle Scholar
  124. Kirsh VA, Hayes RB, Mayne ST et al (2006a) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98(4):245–254PubMedGoogle Scholar
  125. Kirsh VA, Mayne ST, Peters U et al (2006b) A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(1):92–98PubMedGoogle Scholar
  126. Kirsh VA, Peters U, Mayne ST et al (2007) Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 99(15):1200–1209PubMedGoogle Scholar
  127. Kolonel LN (2001) Fat, meat, and prostate cancer. Epidemiol Rev 23(1):72–81PubMedGoogle Scholar
  128. Kolonel LN, Yoshizawa CN, Hankin JH (1988) Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 127:999–1012PubMedGoogle Scholar
  129. Kolonel LN, Hankin JH, Whittemore AS et al (2000) Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 9(8):795–804PubMedGoogle Scholar
  130. Korodi Z, Wang X, Tedeschi R (2005) No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. J Infect Dis 191(12):2008–2011PubMedGoogle Scholar
  131. Kristal AR, Lampe JW (2002) Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer 42(1):1–9PubMedGoogle Scholar
  132. Kristal AR, Stanford JL, Cohen JH et al (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8:887–892PubMedGoogle Scholar
  133. Kurahashi N, Iwasaki M, Sasazuki S (2007) Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 16(3):538–545PubMedGoogle Scholar
  134. Kuriyama M, Wang MC, Lee CI et al (1981) Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41(10):3874–3876PubMedGoogle Scholar
  135. Langeberg WJ, Isaacs WB, Stanford JL (2007) Genetic etiology of hereditary prostate cancer. Front Biosci 12:4101–4110PubMedGoogle Scholar
  136. Lawson KA, Wright ME, Subar A et al (2007) Multivitamin use and risk of prostate cancer in the National Institutes of Health – AARP Diet and Health Study. J Natl Cancer Inst 99(10):754–764PubMedGoogle Scholar
  137. Lee AK, D’Amico AV (2005) Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23(32):8192–8197PubMedGoogle Scholar
  138. Lee IM, Sesso HD, Chen JJ et al (2001) Does physical activity play a role in the prevention of prostate cancer? Epidemiol Rev 23(1):132–137PubMedGoogle Scholar
  139. Lee IM, Gaziano JM, Buring JE (2006) Vitamin E in the prevention of prostate cancer: where are we today? J Natl Cancer Inst 98(4):225–227PubMedGoogle Scholar
  140. Leitzmann MF, Stampfer MJ, Wu K et al (2003) Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95(13):1004–1007PubMedGoogle Scholar
  141. Leitzmann MF, Platz EA, Stampfer MJ et al (2004a) Ejaculation frequency and subsequent risk of prostate cancer. JAMA 291(13):1578–1586PubMedGoogle Scholar
  142. Leitzmann MF, Stampfer MJ, Michaud DS et al (2004b) Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 80(1):204–216PubMedGoogle Scholar
  143. Li H, Stampfer MJ, Hollis JB et al (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103PubMedGoogle Scholar
  144. Liang T, Liao S (1992) Inhibition of steroid 5 alpha reductase by specific aliphatic unsaturated fatty acids. Biochem J 285:557–562PubMedGoogle Scholar
  145. Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85PubMedGoogle Scholar
  146. Lippman SM, Goodman PJ, Klein EA et al (2005) Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97(2):94–102PubMedGoogle Scholar
  147. Littman AJ, Kristal AR, White E (2006) Recreational physical activity and prostate cancer risk (United States). Cancer Causes Control 17(6):831–841PubMedGoogle Scholar
  148. Littman AJ, White E, Kristal AR (2007) Anthropometrics and prostate cancer risk. Am J Epidemiol 165(11):1271–1279PubMedGoogle Scholar
  149. Liu SE, Lee IM, Linson P et al (2000) A prospective study of physical activity and risk of prostate cancer in US physicians. Int J Epidemiol 29:29–35PubMedGoogle Scholar
  150. Liu X, Plummer SJ, Nock NL et al (2006) Non steroidal anti inflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 164(10):984–989PubMedGoogle Scholar
  151. Lotufo PA, Lee IM, Ajani UA et al (2000) Cigarette smoking and risk of prostate cancer in the Physicians’ Health Study. Int J Cancer 87:141–144PubMedGoogle Scholar
  152. Lumey LH (1996) Prostate cancer and smoking: a review of case-control and cohort studies. Prostate 29:249–260PubMedGoogle Scholar
  153. Lund-Nilsen TI, Johnsen R, Vatten LJ (2000) Socio-economic and lifestyle factors associated with the risk of prostate cancer. Br J Cancer 82:1358–1363PubMedGoogle Scholar
  154. MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003PubMedGoogle Scholar
  155. MacInnis RJ, English DR, Gertig DM et al (2003) Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 12(12):1417–1421PubMedGoogle Scholar
  156. MacLennan GT, Eisenberg R, Fleshman RL et al (2006) The influence of chronic inflammation in prostatic carcinogenesis: a 5-year follow up study. J Urol 176(3):1012–1016PubMedGoogle Scholar
  157. Mannisto S, Pietinen P, Virtanen MJ et al (2003) Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. Cancer Epidemiol Biomarkers Prev 12(12):1422–1428PubMedGoogle Scholar
  158. Mawson CA, Fischer MI (1952) Occurrence of zinc in human prostate gland. Canad J Med Sci 30:336–339Google Scholar
  159. McNeal JE (1981) The zonal anatomy of the prostate. Prostate 2:35–49PubMedGoogle Scholar
  160. McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12:S122–S128PubMedGoogle Scholar
  161. Meinbach DS, Lokeshwar BL (2006) Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? Urol Oncol 24(4):294–306PubMedGoogle Scholar
  162. Meyer F, Galan P, Douville P et al (2005) Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 116:182–186PubMedGoogle Scholar
  163. Michaud DS, Augustsson K, Rimm EB et al (2001) A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 12(6):557–567PubMedGoogle Scholar
  164. Michaud DS, Daugherty SE, Berndt SI (2006) Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66(8):4525–4530PubMedGoogle Scholar
  165. Mikhak B, Hunter DJ, Spiegelman D et al (2007) Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67(9):911–923PubMedGoogle Scholar
  166. Mitrou PN, Albanes D, Weinstein SJ et al (2007) A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). Int J Cancer 120(11):2466–2473PubMedGoogle Scholar
  167. Montuschi P, Barnes P, Roberts LJ 2nd (2007) Insights into oxidative stress: the isoprostanes. Curr Med Chem 14(6):703–717PubMedGoogle Scholar
  168. Moreno J, Krishnan AV, Peehl DM et al (2006) Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 26(4A):2525–2530PubMedGoogle Scholar
  169. Myers CE, Ghosh J (1999) Lipoxygenase inhibition in prostate cancer. Eur Urol 35(5–6):395–398PubMedGoogle Scholar
  170. Navarro Silvera SA, Rohan TE (2007) Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control 18(1):7–27PubMedGoogle Scholar
  171. Nilsen TI, Romundstad PR, Troisi R et al (2005) Birth size and subsequent risk for prostate cancer: a prospective population-based study in Norway. Int J Cancer 113(6):1002–1004PubMedGoogle Scholar
  172. Nilsen TI, Romundstad PR, Vatten LJ (2006) Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer 119(12):2943–2947PubMedGoogle Scholar
  173. Norrish AE, Jackson RT, McRae CU (1998) Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 77:511–515PubMedGoogle Scholar
  174. Norrish AE, Ferguson LR, Knize MG et al (1999) Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 91:2038–2044PubMedGoogle Scholar
  175. Omenn GS, Goodman GE, Thornquist MD et al (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88:1550–1559PubMedGoogle Scholar
  176. Ostrander EA, Stanford JL (2000) Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 67:1367–1375PubMedGoogle Scholar
  177. Ostrander EA, Markianos K, Stanford JL (2004) Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 5:151–175PubMedGoogle Scholar
  178. Page WF, Braun MM, Partin AW et al (1997) Heredity and prostate cancer: a study of World War II veteran twins. Prostate 33(4):240–245PubMedGoogle Scholar
  179. Palapattu GS, Sutcliffe S, Bastian PJ et al (2005) Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26(7):1170–1181PubMedGoogle Scholar
  180. Papatsoris AG, Karamouzis MV, Papavassiliou AG (2005) Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med 11(2):52–55PubMedGoogle Scholar
  181. Park SY, Murphy SP, Wilkens LR et al (2007a) Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer 121(6):1339–1345PubMedGoogle Scholar
  182. Park SY, Murphy SP, Wilkens LR et al (2007b) Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 166:1259–1269PubMedGoogle Scholar
  183. Park Y, Mitrou PN, Kipnis V et al (2007c) Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol 166:1270–1279PubMedGoogle Scholar
  184. Parkin DM, Muir C, Waterhouse J et al (eds) (1992) Cancer incidence in five continents, vol 6. IARC, LyonGoogle Scholar
  185. Parkin DM, Whelan SL, Ferlay J et al (eds) (2002) Cancer incidence in five continents, vol 8. IARC, LyonGoogle Scholar
  186. Pashayan N, Powles J, Brown C et al (2006) Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br J Cancer 95(3):401–405PubMedGoogle Scholar
  187. Patel AV, Rodriguez C, Jacobs EJ et al (2005) Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev 14(1):275–279PubMedGoogle Scholar
  188. Patel AA, Chen MH, Renshaw AA et al (2007) PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 298(13):1533–1538PubMedGoogle Scholar
  189. Peehl DM, Skowronski RJ, Leung GK et al (1994) Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805–810PubMedGoogle Scholar
  190. Peng L, Wang J, Malloy PJ et al (2007) The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer 122(3):558–566Google Scholar
  191. Peters U, Foster CB, Chatterjee N et al (2007a) Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr 85(1):209–217PubMedGoogle Scholar
  192. Peters U, Leitzmann MF, Chatterjee N et al (2007b) Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 16(5):962–968PubMedGoogle Scholar
  193. Peters U, Littman AJ, Kristal AR et al (2008) Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control 19(1):75–87PubMedGoogle Scholar
  194. Platz EA (2002) Energy imbalance and prostate cancer. J Nutr 132(11 Suppl):3471S–3481SPubMedGoogle Scholar
  195. Platz EA, De Marzo AM (2004) Epidemiology of inflammation and prostate cancer. J Urol 171(2 Pt 2):S36–S40PubMedGoogle Scholar
  196. Platz EA, Giovannucci E (2004) The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92(4):237–253PubMedGoogle Scholar
  197. Platz EA, Helzlsouer KJ (2001) Selenium, zinc, and prostate cancer. Epidemiol Rev 23(1):93–101PubMedGoogle Scholar
  198. Platz EA, Giovannucci E, Rimm EB et al (1998) Retrospective analysis of birth weight and prostate cancer in the Health Professionals Follow-up Study. Am J Epidemiol 147(12):1140–1144PubMedGoogle Scholar
  199. Platz EA, Helzlsouer KJ, Hoffman SC et al (2002) Prediagnostic toenail cadmium and zinc and subsequent prostate cancer risk. Prostate 52(4):288–296PubMedGoogle Scholar
  200. Platz EA, Leitzmann MF, Michaud DS et al (2003) Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 63(23):8542–8548PubMedGoogle Scholar
  201. Platz EA, De Marzo AM, Giovannucci E (2004a) Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem 91(3):553–571PubMedGoogle Scholar
  202. Platz EA, Leitzmann MF, Rimm EB et al (2004b) Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. Am J Epidemiol 159(5):444–453PubMedGoogle Scholar
  203. Platz EA, Leitzmann MF, Rifai N et al (2005a) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14(5):1262–1269PubMedGoogle Scholar
  204. Platz EA, Pollak MN, Leitzmann MF et al (2005b) Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 16(3):255–262PubMedGoogle Scholar
  205. Presti JC Jr (2007) Prostate biopsy strategies. Nat Clin Pract Urol 4(9):505–511PubMedGoogle Scholar
  206. Preston DL, Ron E, Tokuoka S et al (2007) Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiat Res 168(1):1–64PubMedGoogle Scholar
  207. Prins GS, Huang L, Birch L et al (2006) The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci 1089:1–13PubMedGoogle Scholar
  208. Prinsac GS, Birch L, Habermann H et al (2001) Influence of neonatal estrogens on rat prostate development. Reprod Fertil Dev 13(4):241–252Google Scholar
  209. Purnell JQ, Bland LB, Garzotto M et al (2006) Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. J Lipid Res 47(2):349–355PubMedGoogle Scholar
  210. Putnam SD, Cerhan JR, Parker AS et al (2000) Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 10(6):361–369PubMedGoogle Scholar
  211. Rafnsson V (2007) Farming and prostate cancer. Occup Environ Med 64(3):143PubMedGoogle Scholar
  212. Randall VA (1994) Role of 5 alpha-reductase in health and disease. Baillieres Clin Endocrinol Metab 8(2):405–431PubMedGoogle Scholar
  213. Raynaud JP (2006) Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 102(1–5):261–266PubMedGoogle Scholar
  214. Renehan AG, Zwahlen M, Minder C et al (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353PubMedGoogle Scholar
  215. Ribeiro R, Lopes C, Medeiros R (2006) The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives. Prostate Cancer Prostatic Dis 9(1):19–24PubMedGoogle Scholar
  216. Risbridger GP, Ellem SJ, McPherson SJ (2007) Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 39(3):183–188PubMedGoogle Scholar
  217. Risch N (2001) The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev 10(7):733–741PubMedGoogle Scholar
  218. Roberts RO, Bergstralh EJ, Bass SE et al (2004) Prostatitis as a risk factor for prostate cancer. Epidemiology 15(1):93–99PubMedGoogle Scholar
  219. Roddam AW, Severi G, English DR, Giles GG, The Endogenous Hormones and Prostate Cancer Collaborative Group (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of eighteen prospective studies. J Natl Cancer Inst 100(3):170–183PubMedGoogle Scholar
  220. Rodriguez C, Jacobs EJ, Mondul AM et al (2004) Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 13(3):378–382PubMedGoogle Scholar
  221. Rodriguez C, McCullough ML, Mondul AM et al (2006) Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 15(2):211–216PubMedGoogle Scholar
  222. Rodriguez C, Freedland SJ, Deka A et al (2007) Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16(1):63–69PubMedGoogle Scholar
  223. Rohrmann S, Platz EA, Kavanaugh CJ et al (2007) Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. Cancer Causes Control 18(1):41–50PubMedGoogle Scholar
  224. Rosenblatt KA, Carter JJ, Iwasaki LM et al (2003) Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 12(8):763–768PubMedGoogle Scholar
  225. Ross RK, Schottenfeld D (1996) Prostate cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention. Oxford University Press, Oxford, pp 1180–1206Google Scholar
  226. Ross RK, Pike MC, Coetzee GA et al (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58:4497–4504PubMedGoogle Scholar
  227. Rotkin ID (1977) Studies in the epidemiology of prostatic cancer: expanded sampling. Cancer Treat Rep 61(2):173–180PubMedGoogle Scholar
  228. Schaid DJ (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13(Spec No 1):R103–R121PubMedGoogle Scholar
  229. Schaid DJ, Stanford JL, McDonnell SK et al (2007) Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet 121(6):729–735PubMedGoogle Scholar
  230. Schiel R, Beltschikow W, Steiner T et al (2006) Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 28(3):169–175PubMedGoogle Scholar
  231. Schoonen WM, Salinas CA, Kiemeney LA et al (2005) Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 113(1):133–140PubMedGoogle Scholar
  232. Schroder FH (1994) The European screening study for prostate cancer. Can J Oncol 4(Suppl 1):102–105PubMedGoogle Scholar
  233. Schuurman AG, Goldbohm RA, Dorant E et al (1998) Vegetable and fruit consumption and prostate cancer risk: a cohort study in The Netherlands. Cancer Epidemiol Biomarkers Prev 7(8):673–680PubMedGoogle Scholar
  234. Schwartz GG, Wang MH, Zang M (1997) 1 alpha, 25- dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727–732PubMedGoogle Scholar
  235. Sciarra A, Di Silverio F, Salciccia S et al (2007) Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52(4):964–972PubMedGoogle Scholar
  236. Severi G, Morris HA, MacInnis RJ et al (2006a) Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(6):1137–1141PubMedGoogle Scholar
  237. Severi G, Morris HA, MacInnis RJ et al (2006b) Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(1):86–91PubMedGoogle Scholar
  238. Shahedi K, Lindström S, Zheng SL et al (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119(3):668–672PubMedGoogle Scholar
  239. Shahinian VB, Kuo YF, Freeman JL et al (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103(8):1615–1624PubMedGoogle Scholar
  240. Shinohara K (2006) Improving cancer detection by prostate biopsy: the role of core number and site. Nat Clin Pract Urol 3(10):526–527PubMedGoogle Scholar
  241. Singh R, Eeles RA, Durocher F et al (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis 3(4):241–247PubMedGoogle Scholar
  242. Sinha R, Rothman N (1999) Role of well-done, grilled red meat, heterocyclic amines (HCAs) in the etiology of human cancer. Cancer Lett 143(2):189–194PubMedGoogle Scholar
  243. Smith DP, Armstrong BK (1998) Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 169:17–20PubMedGoogle Scholar
  244. Sooriakumaran P, Kaba R (2005) The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review. Int J Surg 3(4):278–285PubMedGoogle Scholar
  245. Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317(15):909–916PubMedGoogle Scholar
  246. Stattin P, Lumme S, Tenkanen L et al (2004a) High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108(3):418–424PubMedGoogle Scholar
  247. Stattin P, Rinaldi S, Biessy C et al (2004b) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based non screened cohort. J Clin Oncol 22(15):3104–3112PubMedGoogle Scholar
  248. Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp Biol Med (Maywood) 229:277–284Google Scholar
  249. Stram DO, Hankin JH, Wilkens LR et al (2006) Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study (United States). Cancer Causes Control 17(9):1193–1207PubMedGoogle Scholar
  250. Sun J, Wiklund F, Zheng SL et al (2005) Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 97(7):525–532PubMedGoogle Scholar
  251. Sun J, Wiklund F, Hsu FC et al (2006) Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev 15(3):480–485PubMedGoogle Scholar
  252. Sun J, Turner A, Xu J et al (2007) Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 25(3):250–259PubMedGoogle Scholar
  253. Sutcliffe S, Giovannucci E, Alderete JF et al (2006a) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(5):939–945PubMedGoogle Scholar
  254. Sutcliffe S, Giovannucci E, De Marzo AM et al (2006b) Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2160–2166PubMedGoogle Scholar
  255. Sutcliffe S, Giovannucci E, Gaydos CA et al (2007a) Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 16(8):1573–1580PubMedGoogle Scholar
  256. Sutcliffe S, Giovannucci E, Leitzmann MF (2007b) A prospective cohort study of red wine consumption and risk of prostate cancer. Int J Cancer 120(7):1529–1535PubMedGoogle Scholar
  257. Tang D, Liu JJ, Rundle A, Neslund-Dudas C et al (2007) Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomarkers Prev 16(4):803–808PubMedGoogle Scholar
  258. Telesca D, Etzioni R, Gulati R (2008) Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64(1):10–19PubMedGoogle Scholar
  259. Thomas DB, Karagas MR (1987) Cancer in first and second generation Americans. Cancer Res 47:5771–5776PubMedGoogle Scholar
  260. Thompson D, Easton D (2004) The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 9(3):221–236PubMedGoogle Scholar
  261. Tibblin G, Eriksson M, Cnattingius S et al (1995) High birthweight as a predictor of prostate cancer risk. Epidemiology 6(4):423–424PubMedGoogle Scholar
  262. Torniainen S, Maria Hedelin M, Autio V et al (2007) Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland. Cancer Epidemiol Biomarkers Prev 16(5):956–961PubMedGoogle Scholar
  263. Travis RC, Key TJ, Allen NE et al (2007) Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121(6):1331–1338PubMedGoogle Scholar
  264. Tretli S, Engeland A, Haldorsen T et al (1996) Prostate cancer – look to Denmark? J Natl Cancer Inst 88(2):128PubMedGoogle Scholar
  265. Tseng M, Breslow RA, DeVellis RF et al (2004) Dietary patterns and prostate cancer risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study cohort. Cancer Epidemiol Biomarkers Prev 13(1):71–77PubMedGoogle Scholar
  266. UICC (International Union Against Cancer) (2002) TNM Classification of malignant tumours, 6th edn. Sobin LH, Wittekind Ch (eds) Wiley, New YorkGoogle Scholar
  267. Vainio H (1999) Chemoprevention of cancer: a controversial and instructive story. Br Med Bull 55(3):593–599PubMedGoogle Scholar
  268. van Leenders G (2007) Despite extensive efforts, the validation of prognostic tissue markers in prostate cancer has not yet resulted in the widespread implementation of novel diagnostic tests. Eur Urol 52(1):125PubMedGoogle Scholar
  269. Velicer CM, Kristal A, White E (2006) Alcohol use and the risk of prostate cancer: results from the VITAL cohort study. Nutr Cancer 56(1):50–56PubMedGoogle Scholar
  270. Verhoeven DT, Verhagen H, Goldbohm RA et al (1997) Review of mechanisms underlying anticarcinogenesis by brassica vegetables. Chem Biol Interact 103:79–129PubMedGoogle Scholar
  271. vom Saal FS, Timms BG, Montano MM et al (1997) Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 94:2056–2061PubMedGoogle Scholar
  272. Walker M, Aronson KJ, King W et al (2005) Dietary patterns and risk of prostate cancer in Ontario, Canada. Int J Cancer 116(4):592–598PubMedGoogle Scholar
  273. Wallstrom P, Bjartell A, Gullberg B et al (2007) A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden). Cancer Causes Control 18(10):1107–1121PubMedGoogle Scholar
  274. Weigel NL (2007) Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev 65(8 Pt 2):S116–S117PubMedGoogle Scholar
  275. Weinstein SJ, Wright ME, Lawson KA (2007) Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16(6):1253–1259PubMedGoogle Scholar
  276. Weiss JM, Huang WY, Rinaldi S et al (2007) IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 121(10):2267–2273PubMedGoogle Scholar
  277. West DW, Slattery ML, Robison LM et al (1991) Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2:85–94PubMedGoogle Scholar
  278. Whitacre DC, Chauhan S, Davis T et al (2002) Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 13:1–11PubMedGoogle Scholar
  279. Whittemore AS, Wu AH, Kolonel LN et al (1995) Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 141(8):732–740PubMedGoogle Scholar
  280. Wilson JM, Jungner YG (1968) Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 65(4):281–393PubMedGoogle Scholar
  281. Wilt TJ (2008) SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care. J Natl Cancer Inst 100(16):1123–1125PubMedGoogle Scholar
  282. Winter ML, Bosland MC, Wade DR et al (1995) Induction of benign prostatic hyperplasia in intact dogs by near-physiological levels of 5 alpha-dihydrotestosterone and 17 beta-estradiol. Prostate 26(6):325–333PubMedGoogle Scholar
  283. Wiren S, Stocks T, Rinaldi S et al (2007) Androgens and prostate cancer risk: a prospective study. Prostate 67(11):1230–1237PubMedGoogle Scholar
  284. Wright ME, Weinstein S, Lawson KA et al (2007a) Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 16(6):1128–1135PubMedGoogle Scholar
  285. Wright ME, Chang SC, Schatzkin A et al (2007b) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675–684PubMedGoogle Scholar
  286. Wu JD, Haugk K, Woodke L et al (2006a) Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99(2):392–401PubMedGoogle Scholar
  287. Wu K, Hu FB, Willett WC (2006b) Dietary patterns and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 15(1):167–171PubMedGoogle Scholar
  288. Yan L, Spitznagel EL (2005) Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 117(4):667–669PubMedGoogle Scholar
  289. Yasumaru M, Tsuji S, Tsujii M et al (2003) Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 63(20):6726–6734PubMedGoogle Scholar
  290. Yatani R, Chigusa I, Akazaki K et al (1982) Geographic pathology of latent prostatic carcinoma. Int J Cancer 29:611–616PubMedGoogle Scholar
  291. Zappa M, Ciatto S, Bonardi R et al (1998) Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 9(12):1297–1300PubMedGoogle Scholar
  292. Zeegers MP, Jellema A, Ostrer H (2003) Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 97(8):1894–1903PubMedGoogle Scholar
  293. Zeegers MP, Dirx MJ, van den Brandt PA (2005) Physical activity and the risk of prostate cancer in the Netherlands cohort study, results after 9.3 years of follow-up. Cancer Epidemiol Biomarkers Prev 14(6):1490–1495PubMedGoogle Scholar
  294. Zheng SL, Augustsson-Bälter K, Chang B et al (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 64(8):2918–2922PubMedGoogle Scholar
  295. Zheng SL, Liu W, Wiklund F et al (2006) A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate 66(14):1556–1564PubMedGoogle Scholar
  296. Zhou JR, Blackburn GL (1997) Bridging animal and human studies: what are the missing segments in dietary fat and prostate cancer? Am J Clin Nutr 66:1572S–1580SPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Cancer Epidemiology Centre, The Cancer Council VictoriaCarltonAustralia

Personalised recommendations